Moreover, Zhu et al. reported that higher levels of IL-6 and soluble SDF1α are associated with rapid progression or mortality with sunitinib treatment in patients with advanced HCC [76] (Table 2). Here, CXCL12 is linked to hepatocellular carcinoma.